Compare Abbott Laboratories (ABT) vs Wayfair Inc (W) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Wayfair Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Wayfair Inc trades at $86.87 (market cap $12.31B). The key difference: Abbott Laboratories is far larger — about 13.6× Wayfair Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| ABT | W | |
|---|---|---|
Market Cap | $166.94B | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $119.05 |
52-Week Low | $82.57 | $53.37 |
Enterprise Value | $193.69B | $14.88B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Wayfair (W) trades at $93.18, down 1.4% today, with a bullish technical outlook supported by moving averages and positive momentum indicators. The company shows mixed fundamentals with strong revenue growth to $12.46B in 2025 but negative net income margins of -2.41%. Recent analyst upgrades to Strong Buy highlight optimism around earnings potential, though high debt levels and competitive pressures remain concerns.
Investment outlook balances strong analyst support (52% buy ratings) against fundamental challenges including negative profitability and elevated debt. The stock offers momentum potential with upcoming Q2 earnings on August 4, 2026 as a key catalyst, but requires careful monitoring of margin improvement and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
